COLOPL Group Blockchain Game Company Brilliantcrypto, Confirms Partnership with Coincheck Ahead of IEO
20.7.2023 09:00:00 EEST | Business Wire | Press release
Brilliantcrypto, Inc. (HQ: Minato City Tokyo, CEO: Naruatsu Baba, henceforth “Brilliantcrypto”) has partnered with the crypto asset trading service provider Coincheck, Inc. (HQ: Shibuya City Tokyo, CEO: Satoshi Hasuo, henceforth “Coincheck”) ahead of an IEO※1 (Initial Exchange Offering, henceforth “IEO”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230719966068/en/
Brilliantcrypto
Brilliantcrypto was established in November 2022 as a wholly owned subsidiary of COLOPL, Inc. (CEO: Takashi Miyamoto, HQ: Minato City Tokyo), to carry out GameFi※2 projects using blockchain technology.
With this partnership, and through the interconnected business of Brilliantcrypto’s currently in-development blockchain game and Coincheck’s crypto asset trading service, the two companies will work together in creating a new game experience and GameFi market on the global stage.
The large-scale Japanese blockchain game project currently in development shall introduce “Proof of Gaming,” a new concept that works for the benefit of others (through guaranteeing value), inspired by the “Proof of Work”※3 mechanism of Bitcoin. Through doing this, it aims to make sustainable play-to-earn※4 a reality.
By utilizing the crypto asset exchange user base and sales network of Coincheck, which is the largest scale exchange and has the best track record with IEOs among domestic crypto exchanges, Brilliantcrypto plans to acquire trust, and aims to achieve a highly enthusiastic user base from the launch period of the game.
Brilliantcrypto will be holding a presentation on July 25th 14:00 JST at the “WebX 2023” event, which will be held at the Tokyo International Forum on July 25th and July 26th. WebX 2023 is a large-scale global conference where the main players in Web3 from countries around the world will gather. On the day, the founder and current chairman of COLOPL, Inc., Mr. Naruatsu Baba will be presenting.
You can view the online livestream by following the link below.
https://www.youtube.com/watch?v=0iEFIMpkf9Q
Comment from Isaka Tomoyuki (Coincheck, Vice-President, Executive Committee Member & Crypto Asset Operations Department Manager)
The GameFi market is still developing, and there is a demand for this new type of game experience that combines finance and entertainment using blockchain technology. Currently, there are many debates taking place about GameFi around the world. But I believe that between theorizing about it, and actually shaping it into something that you can implement into the design of a game that is actually playable, there exists an extraordinarily large gap.
The COLOPL group and its Chief Creator Naruatsu Baba are a rare force in the industry that bridges that gap by delivering original game design aligned with new eras in the gaming industry to their users. I am therefore very pleased to be working on an IEO with the creative team from Brilliantcrypto which is spearheaded by Mr. Baba.
As a leading company for IEOs and crypto asset exchange in Japan, we want to put our full support behind companies that aim to develop the Web3/Crypto industry, or creators that are giving this new type of game design a challenge.
Comment from Naruatsu Baba (CEO of Brilliantcrypto)
Brilliantcrypto was established to take on the challenges of blockchain gaming, and create games that truly shine and stand out. We feel empowered and elated that Coincheck felt a deep connection with our vision “to harness the power of games and blockchain technology to create new value,” and thus decided to become our IEO partner.
Through the partnership of our company, which has spent many years using technology and individualistic ideas to carry out business in the mobile gaming industry, with Coincheck, the largest cryptocurrency exchange in the domestic market, we aim to make a huge impact in not only the Japanese Web3 industry, or even just in the gaming industry, but in all areas of the world.
On July 25th at the WebX 2023 event, which is to be held at the Tokyo International Forum, I plan to deliver a presentation personally and reveal the project to the world. Please look forward to our project, which will bring a never-seen-before, new type of value out into the world.
※1: IEO describes the public offering, sale, and distribution of crypto assets (tokens) that takes place after a project audit/inspection with crypto assets exchange as the medium, following the rules of the Japanese domestic regulation. Until now there have been 4 examples of IEOs performed domestically. Coincheck has carried out two of these including the very first domestic IEO, through the Coincheck IEO platform.
※2: GameFi is a word that combines Game and Finance to describe games that include mechanisms through which one can earn through gameplay, which is made possible by integrating blockchain technology with crypto assets.
※3: Proof of Work (PoW) is one of the consensus algorithms that allows crypto assets to be mined. It allows the transaction and sending of crypto assets, starting with Bitcoin, to be correctly recorded on the blockchain through calculations and verification work. This calculation and verification work is called “mining,” and those who carry it out are called “miners.” PoW is the process in which agreement is reached that the data is correct between the miners through mining.
※4: Play-to-earn is a concept which describes games which make it possible to earn through gameplay, made possible by integrating blockchain technology with crypto assets.
■About Coincheck
Coincheck, Inc. operates a crypto assets exchange platform which for 4 years in a row, has been No.1 in application downloads in that category*. Coincheck’s mission is “Making Exchange of New Values Easier.” Using a foundation of the latest technology and the highest level of security, it aims to create the best service whereby users can feel closer to the “exchange of new values,” which is brought about through crypto assets and blockchain technology.
*Scope: Domestic Crypto Assets Exchange Platforms. Period: 2019/01〜2022/12 Data from App Tweak
Company Name: Coincheck, Inc.
Headquarters: Tokyo, Shibuya City, Maruyamacho, 3-6, 12F E. Space Tower
Founded: 2012/08/28
Executive Director: Satoshi Hasuo
Crypto Asset Exchange Business Registration: Kanto Local Finance Bureau No. 00014
Coincheck, Inc. Corporate Site: https://corporate.coincheck.com/
■About Brilliantcrypto, Inc.
Brilliantcrypto was established in November 2022 as a wholly owned subsidiary by COLOPL, Inc., to carry out GameFi projects using blockchain technology. It was established to take on the challenges of blockchain gaming, and create games that truly shine and stand out. Using both blockchain technology, and the bountiful knowledge gained through the COLOPL group’s many years creating video games, we will create new value on a global scale.
Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba
Brilliantcrypto, Inc. Corporate Site: https://brypto.net
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719966068/en/
Contact information
<Point of Contact regardings inquiries from the media on this release>
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail: press.contact@brilliantcrypto.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
